An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
First launches expected in H1 2022
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Subscribe To Our Newsletter & Stay Updated
